Advertisement

Current Sexual Health Reports

, Volume 8, Issue 4, pp 231–239 | Cite as

Adjunct Management of Male Hypogonadism

  • Phil Vu Bach
  • Bobby B. Najari
  • James A. Kashanian
Male Sexual Dysfunction and Disorders (AW Pastuszak and TS Köhler, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Male Sexual Dysfunction and Disorders

Abstract

While testosterone replacement therapy (TRT) has been the main strategy in the management of male hypogonadism, the significant risks associated with TRT have driven the search for alternative strategies to treat hypogonadism. With the high preponderance of secondary and mixed-dysfunction hypogonadism, medications such as clomiphene citrate, aromatase inhibitors, and human chorionic gonadotropin (HCG), which target the hypothalamus/pituitary portions of the hypothalamus-pituitary-gonadal axis, have increasingly been studied despite not being FDA-approved for treatment of male hypogonadism. While these agents have demonstrated some promise in managing male hypogonadism, the current evidence behind their use remains weak and there is a need for well-designed, prospective trials that can further elucidate the roles for these agents in the management of male hypogonadism.

Keywords

Hypogonadism Clomiphene citrate Aromatase inhibitor Human chorionic gonadotropin (HCG) Testosterone 

Notes

Compliance with Ethical Standards

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Funding

PVB and BBN were supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59. doi: 10.1210/jc.2009-2354. CrossRefPubMedGoogle Scholar
  2. 2.
    Jungwirth A, Giwercman A, Tournaye H, et al. European association of urology guidelines on male infertility: the 2012 update. Eur Urol. 2012;62(2):324–32. doi: 10.1016/j.eururo.2012.04.048. CrossRefPubMedGoogle Scholar
  3. 3.
    FC W, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35. doi: 10.1056/NEJMoa0911101. CrossRefGoogle Scholar
  4. 4.
    Brambilla DJ, O'Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol. 2007;67(6):853–62.CrossRefGoogle Scholar
  5. 5.
    Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–81.PubMedGoogle Scholar
  6. 6.
    Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54(10):919–27. doi: 10.1016/j.jacc.2009.04.078. CrossRefPubMedGoogle Scholar
  7. 7.
    Tracz MJ, Sideras K, Bolona ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;91(6):2011–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.CrossRefPubMedGoogle Scholar
  9. 9.
    Moon d G, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (nebido((R))) in testosterone deficiency syndrome in korean: a multicenter prospective study. J Sex Med. 2010;7(6):2253–60. doi: 10.1111/j.1743-6109.2010.01765.x. CrossRefGoogle Scholar
  10. 10••.
    Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611–24. doi: 10.1056/NEJMoa1506119. Given the current controversy surrounding testosterone replacement therapy, this paper is a well-designed trial that provides evidence of moderate benefit in sexual function, mood, and depressive symptoms to testosterone supplementation in older men.CrossRefPubMedGoogle Scholar
  11. 11.
    Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22. doi: 10.1056/NEJMoa1000485. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12••.
    Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36. doi: 10.1001/jama.2013.280386. Despite its flaws, this paper gained widespread coverage in the mainstream media and put the spotlight on potential risks of testosterone replacement therapy. Physicians must know these studies in detail to respond to patient concerns stemming from their findings.CrossRefPubMedGoogle Scholar
  13. 13••.
    Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108. doi: 10.1186/1741-7015-11-108. Despite its flaws, this paper gained widespread coverage in the mainstream media and put the spotlight on potential risks of testosterone replacement therapy. Physicians must know these studies in detail to respond to patient concerns stemming from their findings.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    de Ronde W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod. 2009;24(2):425–8. doi: 10.1093/humrep/den372. CrossRefPubMedGoogle Scholar
  15. 15.
    Stahlman J, Britto M, Fitzpatrick S, et al. Serum testosterone levels in non-dosed females after secondary exposure to 1.62 % testosterone gel: effects of clothing barrier on testosterone absorption. Curr Med Res Opin. 2012;28(2):291–301. doi: 10.1185/03007995.2011.652732. CrossRefPubMedGoogle Scholar
  16. 16.
    Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014;69(6):725–35. doi: 10.1093/gerona/glt154. CrossRefPubMedGoogle Scholar
  17. 17.
    Samplaski MK, Loai Y, Wong K, Lo KC, Grober ED, Jarvi KA. Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters. Fertil Steril. 2014;101(1):64–9. doi: 10.1016/j.fertnstert.2013.09.003. CrossRefPubMedGoogle Scholar
  18. 18.
    Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med. 2010;7(1 Pt 1):269–76. doi: 10.1111/j.1743-6109.2009.01454.x. CrossRefPubMedGoogle Scholar
  19. 19.
    Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. J Clin Endocrinol Metab. 2010;95(4):1810–8. doi: 10.1210/jc.2009-1796. CrossRefPubMedGoogle Scholar
  20. 20.
    Cargille CM, Ross GT, Bardin CW. Clomiphene and gonadotrophin in men. Lancet. 1968;2(7581):1298.CrossRefPubMedGoogle Scholar
  21. 21.
    Santen RJ, Leonard JM, Sherins RJ, Gandy HM, Paulsen CA. Short- and long-term effects of clomiphene citrate on the pituitary-testicular axis. J Clin Endocrinol Metab. 1971;33(6):970–9. doi: 10.1210/jcem-33-6-970. CrossRefPubMedGoogle Scholar
  22. 22.
    Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab. 1995;80(12):3546–52. doi: 10.1210/jcem.80.12.8530597. PubMedGoogle Scholar
  23. 23.
    Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res. 2003;15(3):156–65. doi: 10.1038/sj.ijir.3900981. CrossRefPubMedGoogle Scholar
  24. 24.
    Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int. 2012;110(10):1524–8. doi: 10.1111/j.1464-410X.2012.10968.x. CrossRefPubMedGoogle Scholar
  25. 25.
    Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int. 2012;110(4):573–8. doi: 10.1111/j.1464-410X.2011.10702.x. CrossRefPubMedGoogle Scholar
  26. 26.
    Mazzola CR, Katz DJ, Loghmanieh N, Nelson CJ, Mulhall JP. Predicting biochemical response to clomiphene citrate in men with hypogonadism. J Sex Med. 2014;11(9):2302–7. doi: 10.1111/jsm.12592. CrossRefPubMedGoogle Scholar
  27. 27.
    Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. J Urol. 2014;192(3):875–9. doi: 10.1016/j.juro.2014.03.089. CrossRefPubMedGoogle Scholar
  28. 28•.
    Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677–85. doi: 10.1111/bju.13337. This paper presents high quality data on the effectiveness of enclomiphene citrate in both increasing serum testosterone and preserving male fertility.CrossRefPubMedGoogle Scholar
  29. 29.
    Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab. 2004;89(3):1174–80. doi: 10.1210/jc.2003-031467. CrossRefPubMedGoogle Scholar
  30. 30.
    Veldhuis JD, Iranmanesh A. Short-term aromatase-enzyme blockade unmasks impaired feedback adaptations in luteinizing hormone and testosterone secretion in older men. J Clin Endocrinol Metab. 2005;90(1):211–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol. 2009;70(1):116–23. doi: 10.1111/j.1365-2265.2008.03327.x. CrossRefGoogle Scholar
  32. 32.
    Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol. 2002;167(2 Pt 1):624–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int. 2005;16(12):1487–94. doi: 10.1007/s00198-005-1890-8. CrossRefPubMedGoogle Scholar
  34. 34.
    Wickman S, Kajantie E, Dunkel L. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab. 2003;88(8):3785–93. doi: 10.1210/jc.2002-021643. CrossRefPubMedGoogle Scholar
  35. 35•.
    Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011–22. doi: 10.1056/NEJMoa1206168. This paper highlights the complex role played by testosterone and estradiol in male sexual function and raises critical questions on the potential impact of estradiol on male sexual physiology.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Elevated serum estradiol is associated with higher libido in men on testosterone supplementation therapy. Eur Urol. 2014;65(6):1224–5. doi: 10.1016/j.eururo.2014.01.012. CrossRefPubMedGoogle Scholar
  37. 37.
    Helo S, Ellen J, Mechlin C, et al. A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. J Sex Med. 2015;12(8):1761–9. doi: 10.1111/jsm.12944. CrossRefPubMedGoogle Scholar
  38. 38.
    Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril. 2009;92(2):594–604. doi: 10.1016/j.fertnstert.2008.07.1720. CrossRefPubMedGoogle Scholar
  39. 39.
    Dwyer AA, Raivio T, Pitteloud N. Gonadotrophin replacement for induction of fertility in hypogonadal men. Best Pract Res Clin Endocrinol Metab. 2015;29(1):91–103. doi: 10.1016/j.beem.2014.10.005. CrossRefPubMedGoogle Scholar
  40. 40.
    Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European consensus statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11(9):547–64. doi: 10.1038/nrendo.2015.112. PubMedGoogle Scholar
  41. 41.
    Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595–602.CrossRefPubMedGoogle Scholar
  42. 42.
    Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013;189(2):647–50. doi: 10.1016/j.juro.2012.09.043. CrossRefPubMedGoogle Scholar
  43. 43.
    Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab. 2002;87(7):3125–35. doi: 10.1210/jcem.87.7.8630. CrossRefPubMedGoogle Scholar
  44. 44.
    Bayram F, Elbuken G, Korkmaz C, Aydogdu A, Karaca Z, Cakir I. The effects of gonadotropin replacement therapy on metabolic parameters and body composition in men with idiopathic hypogonadotropic hypogonadism. Horm Metab Res. 2016;48(2):112–7. doi: 10.1055/s-0035-1564252. PubMedGoogle Scholar
  45. 45.
    La Vignera S, Condorelli RA, Cimino L, Russo GI, Morgia G, Calogero AE. Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone. Aging Male. 2016;19(1):34–9. doi: 10.3109/13685538.2015.1092021. CrossRefPubMedGoogle Scholar
  46. 46.
    Tsujimura A, Matsumiya K, Takao T, et al. Treatment with human chorionic gonadotropin for PADAM: a preliminary report. Aging Male. 2005;8(3–4):175–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2016

Authors and Affiliations

  • Phil Vu Bach
    • 1
  • Bobby B. Najari
    • 1
  • James A. Kashanian
    • 1
  1. 1.Department of UrologyWeill Cornell MedicineNew YorkUSA

Personalised recommendations